As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Wednesday’s business headlines INDIANAPOLIS (WISH) — Here is a look at Wednesday’s business headlines with Jane ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

Discovery or identification of new product candidates or development of new indications for existing products ... Drug Administration, and no conclusions can or should be drawn regarding the safety or ...

The South African Health Products Regulatory Authority (Sahpra ... Other pharmaceutical players such as Roche, Amgen, Pfizer, ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US ... for pharmaceutical industry products is evolving at pace with new ...